PCSK9 Participates in Oxidized-low Density Lipoprotein-induced Myocardial Injury Through Mitochondrial Oxidative Stress and Drp1-mediated Mitochondrial Fission

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2022 Feb 20

PMID 35184412

Authors

Xuan Li

Fangjie Dai

Hao Wang

Ge Wei

Qiu Jiang

Peipei Yin

ShiJun Wang

Junbo Ge

Cheng Yang

Jian Wu

Yunzeng Zou

Affiliations

Soon will be listed here.

Citing Articles

PCSK9 Inhibitors and Anthracyclines: The Future of Cardioprotection in Cardio-Oncology.

Repp M, Edwards M, Burch C, Rao A, Chinyere I Hearts (Basel). 2024; 5(3):375-388.

PMID: 39268545 PMC: 11391951. DOI: 10.3390/hearts5030027.

The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol.

Dutka M, Zimmer K, Cwiertnia M, Ilczak T, Bobinski R Heart Fail Rev. 2024; 29(5):917-937.

PMID: 38886277 PMC: 11306431. DOI: 10.1007/s10741-024-10409-7.

Targeting mitochondrial dynamics and redox regulation in cardiovascular diseases.

Beg M, Huang M, Vick L, Rao K, Zhang J, Chen Y Trends Pharmacol Sci. 2024; 45(4):290-303.

PMID: 38458847 PMC: 11837222. DOI: 10.1016/j.tips.2024.02.001.

TAK1 Activation by NLRP3 Deficiency Confers Cardioprotection Against Pressure Overload-Induced Cardiomyocyte Pyroptosis and Hypertrophy.

Li X, You J, Dai F, Wang S, Yang F, Wang X JACC Basic Transl Sci. 2024; 8(12):1555-1573.

PMID: 38205342 PMC: 10774584. DOI: 10.1016/j.jacbts.2023.05.008.

PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction.

Matyas C, Trojnar E, Zhao S, Arif M, Mukhopadhyay P, Kovacs A JACC Basic Transl Sci. 2023; 8(10):1334-1353.

PMID: 38094682 PMC: 10715889. DOI: 10.1016/j.jacbts.2023.06.005.

References

Seidah N, Awan Z, Chretien M, Mbikay M . PCSK9: a key modulator of cardiovascular health. Circ Res. 2014; 114(6):1022-36. DOI: 10.1161/CIRCRESAHA.114.301621. View

Facundo H, Brainard R, Caldas F, Brito Lucas A . Mitochondria and Cardiac Hypertrophy. Adv Exp Med Biol. 2017; 982:203-226. DOI: 10.1007/978-3-319-55330-6_11. View

Schluter K, Wolf A, Weber M, Schreckenberg R, Schulz R . Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way. Basic Res Cardiol. 2017; 112(6):63. PMC: 5599470. DOI: 10.1007/s00395-017-0650-1. View

Lin L, Zhou N, Kang L, Wang Q, Wu J, Wang X . Oxidized LDL but not angiotensin II induces cardiomyocyte hypertrophic responses through the interaction between LOX-1 and AT receptors. J Mol Cell Cardiol. 2021; 162:110-118. DOI: 10.1016/j.yjmcc.2021.09.006. View

Davidson S, Duchen M . Endothelial mitochondria: contributing to vascular function and disease. Circ Res. 2007; 100(8):1128-41. DOI: 10.1161/01.RES.0000261970.18328.1d. View

Palee S, McSweeney C, Maneechote C, Moisescu D, Jaiwongkam T, Kerdphoo S . PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid-lowering effects. J Cell Mol Med. 2019; 23(11):7310-7319. PMC: 6815840. DOI: 10.1111/jcmm.14586. View

Ding Z, Wang X, Liu S, Shahanawaz J, Theus S, Fan Y . PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy. Cardiovasc Res. 2018; 114(13):1738-1751. DOI: 10.1093/cvr/cvy128. View

Shirakabe A, Zhai P, Ikeda Y, Saito T, Maejima Y, Hsu C . Drp1-Dependent Mitochondrial Autophagy Plays a Protective Role Against Pressure Overload-Induced Mitochondrial Dysfunction and Heart Failure. Circulation. 2016; 133(13):1249-63. PMC: 4811679. DOI: 10.1161/CIRCULATIONAHA.115.020502. View

Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J . Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res. 2015; 107(4):556-67. DOI: 10.1093/cvr/cvv178. View

10.

Wang X, Li X, Liu S, Brickell A, Zhang J, Wu Z . PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia. Basic Res Cardiol. 2020; 115(6):66. DOI: 10.1007/s00395-020-00832-w. View